Firma b.e.imaging, Autor bei PR-Web

Curium Receives Marketing Authorization In Switzerland For Piflufolastat (18F) – An Innovative PSMA PET Tracer Indicated In Patients With Prostate Cancer

Posted on 20. May 2025 by Firma b.e.imaging Posted in General Tagged ags, beimaging, cancer, clinical, curium, market, nuclear, patients, pet, prostate, psa, psma, spect, therapy, with

Swissmedic grants marketing authorization for Piflufolastat (18F) in Switzerland e.imaging AG is marketing authorization holder and has exclusive distribution rights for Piflufolastat (18F) across Switzerland Curium announced today that it has marketing authorization in Switzerland for the distribution of […]